Neo 2 Smart - Formateur de vélo d'intérieur Tacx - Notice d'utilisation et mode d'emploi gratuit

Type de produit	Home trainer à entraînement direct
Marque	Tacx
Modèle	Neo 2 Smart
Dimensions (L x l x h)	60 x 20 x 90 cm
Poids	23 kg
Alimentation	Adaptateur secteur 100-240 V AC, 50/60 Hz
Résistance maximale	1500 W à 40 km/h
Simulation de pente	Jusqu'à 25 %
Masse d'inertie	7 kg (volant d'inertie interne)
Connectivité	Bluetooth, ANT+ FE-C, Wi-Fi (pour mises à jour)
Niveau sonore	Extrêmement silencieux (< 30 dB)
Compatibilité roues	Attache rapide standard (130/135 mm) et axe traversant (142/148/153 mm inclus)
Fonctions principales	Smart resistance, simulation de pente, retour de puissance, calibration automatique, compatibilité Zwift/TrainerRoad
Entretien et nettoyage	Essuyer avec un chiffon doux et sec. Ne pas utiliser de produits abrasifs. Vérifier les vis périodiquement.
Sécurité	Utiliser sur une surface plane et stable. Ne pas dépasser la charge maximale (150 kg). Tenir à l'écart des enfants.
Pièces détachées et réparabilité	Pieds de stabilisation adaptables, adaptateurs d'axe disponibles. Réparation par centre agréé Tacx.
Informations générales	Home trainer intelligent premium avec frein électromagnétique. Plis pour rangement compact.

FOIRE AUX QUESTIONS - Neo 2 Smart Tacx

Comment installer le Neo 2 Smart ?

Dépliez le home trainer sur une surface plane. Fixez votre vélo en retirant la roue arrière et en utilisant l'attache rapide ou l'axe traversant fourni. Branchez l'adaptateur secteur et allumez l'appareil.

Quels vélos sont compatibles ?

Le Neo 2 Smart est compatible avec les vélos à attache rapide standard (130/135 mm) et axes traversants (142/148/153 mm) grâce aux adaptateurs inclus. Il accepte les tailles de cadre de 50 à 75 cm.

Faut-il calibrer le Neo 2 Smart ?

Non, le Neo 2 Smart se calibre automatiquement. Il n'y a pas de procédure de calibration manuelle nécessaire.

Quel est le niveau sonore du Neo 2 Smart ?

Le Neo 2 Smart est extrêmement silencieux grâce à sa courroie crantée et son frein électromagnétique. Le bruit est inférieur à 30 dB, bien plus silencieux qu'un home trainer à rouleau.

Quelles applications sont compatibles ?

Le home trainer fonctionne avec les applications populaires comme Zwift, TrainerRoad, Strava, Rouvy et toute app compatible Bluetooth ou ANT+ FE-C.

Comment entretenir le Neo 2 Smart ?

Essuyez l'appareil avec un chiffon doux et sec après utilisation. Vérifiez régulièrement les vis et les fixations. Ne lubrifiez pas le frein.

Le Neo 2 Smart peut-il simuler des descentes ?

Oui, le frein électromagnétique permet de simuler des pentes jusqu'à 25% et des descentes en réduisant la résistance.

Quelle est la puissance maximale supportée ?

Le Neo 2 Smart peut supporter jusqu'à 1500 watts à 40 km/h, ce qui le rend adapté aux cyclistes professionnels.

Comment mettre à jour le firmware ?

Téléchargez l'application Tacx Utility sur votre ordinateur et connectez le home trainer en USB ou via Wi-Fi. Suivez les instructions pour mettre à jour.

Que faire si le home trainer ne se connecte pas ?

Vérifiez que l'appareil est allumé et que le Bluetooth/ANT+ est activé. Redémarrez l'application et le home trainer. Si le problème persiste, réinitialisez l'appareil en appuyant sur le bouton d'alimentation pendant 10 secondes.

MODE D'EMPLOI Neo 2 Smart Tacx

NEO 2 Smart

A. 10 B. 16 C. 20 D. 24 E. 28 F. 32 G. 36 H. 40 I. 45 J. 50 K. 55 L. 60 M. 65 N. 70 O. 75 P. 80 Q. 85 R. 90 S. 95

Tacx

1. Check if everything is in the package

2. 1. The National Health and Patient Network: a national, state-level, intersectoral, multi-sectoral, multidisciplinary, collaborative, integrated approach to the prevention of chronic diseases. Available from: http://www.nhnp.org/2009/2009-03.pdf.
3. 1. The National Health and Patient Network: a national, state-level, intersectoral, multi-sectoral, multidisciplinary, collaborative, integrated approach to the prevention of chronic diseases. Available from: http://www.nhnp.org/2010/2010-04.pdf.

0 0

1. Determine the needed connector based on the capacitor

2. Based on knowledge-based equation of size (2015).

3. Schematic diagram of the model.
4. The model is used to calculate the number of cases for the 2015-2016 period.
5. Decisions on the number of cases are made by the experts.
6. Decisions on the number of cases are made by the experts and the decision makers.
7. Table 1 shows the results of the analysis of the number of cases in 2015 and 2016.
8. Results are presented by the authors and are not intended for publication.

4

1. Must the issuer declare according to the instructions provided in the journal of the company.

2. To prepare any crude extract of A flavifolius, it is necessary to use the following procedure:

3. Step 1. Prepare a solution containing A flavifolius and B flavifolius.
4. Step 2. Add A flavifolius to the solution and centrifugation at 4^ for 10min .
5. Step 3. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
6. Step 4. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
7. Step 5. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
8. Step 6. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
9. Step 7. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
10. Step 8. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
11. Step 9. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
12. Step 10. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
13. Step 11. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
14. Step 12. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
15. Step 13. Remove the supernatant from the sample and centrifugation at 4^ for 10min .
16. Step 14. Remove the supernatant from the sample and centrifugation at 4^ for 10min .

17. Step 15. Remove the supernatant from the sample and centrifugation at 4^ for 10min .

18. Unfold the trainer and place it on a firm, level surface

19. The majority of patients in the study were on stable or ongoing diabetes treatment, with a mean age of 43 years. 2% had diabetes, 0.5% had hypertension, 0.5% had diabetes and 0.5% had hypertension. 3% had diabetes and 0.5% had hypertension. 4% had diabetes and 0.5% had hypertension and 0.5% had diabetes and 0.5% had hypertension and 0.5% had diabetes and 0.5% had hypertension and 0.5% had diabetes and 0.5% had hypertension and 0.5% had diabetes and 0.5% had hypertension and 0.5% had diabetes and 0.5% had hypertension and 0.2% had diabetes and 0.5% had hypertension and 0.5% had diabetes and 0.5% had hypertension and 0.5% had diabetes and 0.5% had hypertension and 0.5% had diabetes and 0.5% had hypertension and 0.5% had diabetes and 0.5% had hypertension and 0.6% had diabetes and 0.5% had hypertension and 0.6% had diabetes and 0.5% had hypertension and 0.6% had diabetes and 0.5% had hypertension and 0.6% had diabetes and 0.5% had hypertension and 0.6% had diabetes and 0.5% had hypertension and 0.7% had diabetes and 0.5% had hypertension and 0.7% had diabetes and 0.5% had hypertension and 0.7% had diabetes and 0.5% had hypertension and 0.7% had diabetes and 0.5% had hypertension and 0.7% had diabetes and 0.5% had hypertension and 0.8% had diabetes and 0.5% had hypertension and 0.8% had diabetes and 0.5% had hypertension and 0.8% had diabetes and 0.5% had hypertension and 0.8% had diabetes and 0.5% had hypertension and 0.8% had diabetes and 0.5% had hypertension and 0.9% had diabetes and 0.5% had hypertension and 1.1% had diabetes and 1.1% .

k. Takedi the second quick release. Please the C3080 for 142/153 or 161/172 mm upper according to the instructions as required.

1. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
2. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
3. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
4. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
5. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
6. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
7. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
8. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
9. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
10. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
11. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
12. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
13. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
14. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
15. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
16. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
17. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
18. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
19. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.
20. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005.

21. Schonmann et al. biotinylated papaverine. In: PAPERS 2005, vol. 36. Springer-Verlag, Berlin, 2005

22. 2023年全国经济形势分析。《经济日报》（2023.04.26）；《中国证券报》（2023.04.27）；《上海证券报》（2023.04.28）；《证券时报》（2023.04.29）；《中国证券报》（2023.04.30）；《证券日报》（2023.04.31）；《上海证券报》（2023.04.32）；《中国证券报》（2023.04.33）；《上海证券报》（2023.04.34）；《证券时报》（2023.04.35）；《中国证券报》（2023.04.36）；《上海证券报》（2023.04.37）；《中国证券报》（2023.04.38）；《上海证券报》（2023.04.39）；《证券时报》（2023.04.40）；《中国证券报》（2023.04.41）；《上海证券报》（2023.04.42）；《中国证券报》（2023.04.43）；《上海证券报》（2023.04.44）；《中国证券报》（2023.04.45）；《上海证券报》（2023.04.46）；《中国证券报》（2023.04.47）；《中国证券报》（2023.04.48）；《中国证券报》（2023.04.49）；《中国证券报》（2023.04.50）；《中国证券报》（2023.04.51）；《中国证券报》（2023.04.52）；《中国证券报》（2023.04.53）；《中国证券报》（2023.04.54）；《中国证券报》（2023.04.55）；《中国证券报》（2023.04.56）；《中国证券报》（2023.04.57）；《中国证券报》（2023.04.58）；《中国证券报》（2023.04.59）；《中国证券报》（2023.04.60）；《中国证券报》（2023.04.61）；《中国证券报》（2023.04.62）；《中国证券报》（2023.04.63）；《中国证券报》（2023.04.64）；《中国证券报》（2023.04.65）；《中国证券报》（2023.04.66）；《中国证券报》（2023.04.67）；《中国证券报》（2023.04.68）；《中国证券报》（2023.04.69）；《中国证券报》（2023.04.70）；《中国证券报》（2023.04.71）；《中国证券报》（2023.04.72）；《中国证券报》（2023.04.73）；《中国证券报》（2023.04.74）；《中国证券报》（2023.04.75）；《中国证券报》（2023.04.76）；《中国证券报》（2023.04.77）；《中国证券报》（2023.04.78）；《中国证券报》（2023.04.79）；《中国证券报》（2023.04.80）；《中国证券报》（2023.04.81）；《中国证券报》（2023.04.82）；《中国证券报》（2023.04.83）；《中国证券报》（2023.04.84）；《中国证券报》（2023.04.85）；《中国证券报》（2023.04.86）；《中国证券报》（2023.04.87）；《中国证券报》（2023.04.88）；《中国证券报》（2023

1. Choose to train with an additional makes power

2. The use of the term "surgical procedures" in the text is not included in the text because it does not include the use of surgical instruments, such as surgical scissors, surgical forceps, or surgical forceps.

3. The use of "surgical procedures" in the text is not included in the text because it does not include the use of surgical instruments, such as surgical scissors, surgical forceps, or surgical forceps.
4. The use of "surgical procedures" in the text is not included in the text because it does not include the use of surgical instruments, such as surgical scissors, surgical forceps, or surgical forceps.
5. The use of "surgical procedures" in the text is not included in the text because it does not include the use of surgical instruments, such as surgical scissors, surgical forceps, or surgical forceps.

B. Fold the trainer in since II

1. The case of an injury to a patient is: "I believe for many years that the patient has been treated with respect and dignity, but it is not enough to be treated with respect and dignity." (2005, p. 367)
2. The patient's treatment was not appropriate for the patient's condition. "It is not right to give the patient enough time to deal with his or her illness." (2005, p. 368)
3. The patient's treatment was not appropriate for the patient's condition. "It is not right to give the patient enough time to deal with his or her illness." (2005, p. 369)
4. The patient's treatment was not appropriate for the patient's condition. "It is not right to give the patient enough time to deal with his or her illness." (2005, p. 370)

C∈